1d
MedPage Today on MSNHigh Price of GLP-1 Agents Tip Cost-Benefit Scale UnfavorablyTirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
Medical Xpress on MSN10d
Anti-obesity drugs found to benefit kidney transplant recipients with type 2 diabetesKidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...
Food companies may be able to satisfy the needs of the growing cohort of GLP-1 medication users while also targeting a ...
The administration is reviewing a Centers for Medicare and Medicaid Services rule that would expand coverage to Medicare and Medicaid recipients ...
Illegal networks are flooding the market with counterfeit weight loss drugs, posing a serious threat to public health. The ...
A new study reveals that anti-obesity drugs can help kidney transplant recipients with type 2 diabetes reduce the risk of ...
A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
NEW YORK, March 5, 2025 /PRNewswire/ -- Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived ...
there are effective treatments in the form of multiple FDA-approved anti-obesity medications (AOMs). But for far too many, these medications are inaccessible. Right now, just two percent of people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results